Investment firm HSG to buy Bayer’s Avelox antibiotics business

13 November 2025

Hong Kong-based investment firm HSG has entered into a definitive agreement to acquire the Avelox (moxifloxacin) antibiotics business from Germany’s Bayer (BAYN: DE).

The acquisition includes the Avelox brand, intellectual property and commercial rights across all markets worldwide.

Developed by Bayer and first approved in Europe and the USA in 1999, Avelox is a fluoroquinolone antibiotic primarily prescribed for respiratory tract infections. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

Company Spotlight



More Features in Pharmaceutical